HOME >> BIOLOGY >> NEWS
Clinical study reports findings of combination therapy with DOXIL

h as improvement in disease-related symptoms or increased survival.

How DOXIL Works
DOXIL is an advanced form of doxorubicin, a liposomal formulation of doxorubicin, which means that doxorubicin is encapsulated by a fatty bilayer. The liposome is pegylated, which helps protect the drug from the immune system, resulting in the product circulating in the blood for a longer period of time. The longer circulation allows dosing once every four weeks.

Administration
DOXIL is administered intravenously in the doctor's office or clinic. Treatment usually takes from 30 minutes to one hour, though the first treatment may be longer.

  • To manage adverse events such as PPE, stomatitis, or hematologic toxicity, the dose may be delayed or reduced;
  • Pretreatment with or concomitant use of antiemetics should be considered; and
  • Limited clinical experience exists in treating hepatically impaired patients with DOXIL. Based on experience with doxorubicin HCl, it is recommended that DOXIL dosage be reduced if the bilirubin is elevated as follows: Serum bilirubin 1.2 to 3.0 mg/dL give normal dose, >3.0 mg/dL give normal dose.

Efficacy
DOXIL's refractory ovarian cancer indication was based on the results of three Phase II trials involving patients with metastatic ovarian cancer that was resistant to conventional chemotherapy. Most of the patients had been treated with two or more rounds of conventional chemotherapy, but the tumor was still progressing.

In these studies, patients with refractory metastatic ovarian cancer treated with DOXIL had a 13.8% (20/145) (95% CI 8.1% to 19.3%) combined response rate. The median time to response was 18 weeks, median duration of response was 39 weeks, and median time to disease progression was 16 weeks.

Warnings
In clinical trials, the most common side effects reported with DOXIL therapy included reduced red blood cel
'"/>


8-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Clinical study reports findings combination therapy with DOXIL

(Date:8/27/2014)... of studies have shown that excessive iron ... Parkinson,s disease. Previous studies from Chunyan Guo ... China have shown that baicalin prevented iron ... metal transporter 1 expression, and increased ferroportin ... rotenone-induced Parkinson,s disease rats. However, the relationship ...
(Date:8/27/2014)... has shown that piglets can be weaned later with ... outcome of the study at the University,s Roseworthy campus, ... is an important finding for pig producers. It allows ... production. , "Sows don,t usually start their oestrous cycles ... piglets have been weaned," says Ms Alice Weaver, PhD ...
(Date:8/27/2014)... is a dreaded bacterium that can be found ... few weeks, 28 persons in Denmark have been infected ... supermarkets. 13 have died. , The bacterium is notoriously ... ability to adapt to changes in its surroundings, says ... with colleagues from the Department of Biochemistry and Molecular ...
Breaking Biology News(10 mins):Piglet weaning age no bar to litter frequency 2Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed data of ... Pubmed, has revealed extensive conservation and sharing of specific ... of specific Replikin gene structures has permitted the formulation ... for the H5N1 influenza vaccine and the Taura Syndrome ... be effective (1,2). This Dengue vaccine ...
(Date:8/26/2014)... 2014   Lycera Corp ., a biopharmaceutical ... to treat autoimmune disease and cancer based on ... appointment of Harinder Singh , Ph.D., as ... Singh will lead the board,s efforts to provide ... research programs and pipeline of therapies targeting unmet ...
(Date:8/26/2014)... San Francisco, CA (PRWEB) August 26, 2014 ... to reach USD 8,020.1 million by 2020, according to ... demand for personalized medicine and theranostics, and the subsequent ... be key factors driving market growth over the next ... population and chronic diseases such as cancer, coupled with ...
(Date:8/26/2014)... 26, 2014 Genedata, a leading ... and life science research, today announced the ... be held in Asia, Europe, and North America ... companies and leading research organizations will gather for ... case studies, and upcoming challenges in all areas ...
Breaking Biology Technology:Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3
Cached News: